UNSPSC 51421500: Corticosteroid androstadienes

Corticosteroids made from derivatives of the steroid androstane having two double bonds at any site in any of the rings.

UNSPSC 51421500 Corticosteroid androstadienes is a Class code that shows a significant mismatch between its nominal pharmaceutical scope and the state and local opportunities actually tagged to it. Recent solicitations under this code do not involve corticosteroid medications; instead, they cover naloxone procurement and pharmacy benefit program design. Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for community health initiatives, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, is a market-intelligence inquiry into direct-to-manufacturer prescription programs designed to improve fulfillment efficiency outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. The mismatch between the code's name and actual procurement activity indicates that this code either receives sparse corticosteroid-specific solicitations or is being applied inconsistently to broader pharmaceutical and health-system procurement.

Issuing bodies under this code include county health departments and state health agencies pursuing naloxone distribution and pharmacy-benefit innovation. Geographic activity centers on Florida and Texas based on recent postings. The Seminole County solicitation involves an IFB with a July 26, 2023 response deadline (note: this date predates the posting date and represents a data inconsistency in the source), fixed-fee pricing, E-Verify compliance, and federal FEMA funding compliance. The Texas HHS Commission RFI, with an April 3, 2026 response deadline, is an exploratory mechanism with no formal evaluation criteria or award values stated, designed to inform future RFP strategy for state pharmacy procurement. Neither opportunity specifies set-aside designations. The limited recent activity and the absence of corticosteroid-specific opportunities suggest this code warrants close monitoring but may not represent active pursuit opportunity in its nominal pharmaceutical scope.